In breast cancer, ER-associated protein p97 inhibition increased the expression of multiple stemness and pluripotency regulators, including C/EBPδ, c-MYC, SOX2, and SKP2, by activating the PERK-eif2α pathway, leading to an increase in CSCs [211]. Here, EIF2AK3 is linked to breast cancer.